Suppr超能文献

应用定量效益-风险分析辅助诊断成像领域的监管决策:方法、挑战与机遇。

Applying quantitative benefit-risk analysis to aid regulatory decision making in diagnostic imaging: methods, challenges, and opportunities.

作者信息

Agapova Maria, Devine Emily Beth, Bresnahan Brian W, Higashi Mitchell K, Garrison Louis P

机构信息

Pharmaceutical Outcomes Research and Policy Program, Department of Pharmacy, School of Pharmacy, University of Washington, 1959 NE Pacific St, Seattle, WA 98195.

Pharmaceutical Outcomes Research and Policy Program, Department of Pharmacy, School of Pharmacy, University of Washington, 1959 NE Pacific St, Seattle, WA 98195.

出版信息

Acad Radiol. 2014 Sep;21(9):1138-43. doi: 10.1016/j.acra.2014.05.006.

Abstract

RATIONALE AND OBJECTIVES

Health agencies making regulatory marketing-authorization decisions use qualitative and quantitative approaches to assess expected benefits and expected risks associated with medical interventions. There is, however, no universal standard approach that regulatory agencies consistently use to conduct benefit-risk assessment (BRA) for pharmaceuticals or medical devices, including for imaging technologies. Economics, health services research, and health outcomes research use quantitative approaches to elicit preferences of stakeholders, identify priorities, and model health conditions and health intervention effects.

MATERIALS AND METHODS

Challenges to BRA in medical devices are outlined, highlighting additional barriers in radiology. Three quantitative methods--multi-criteria decision analysis, health outcomes modeling and stated-choice survey--are assessed using criteria that are important in balancing benefits and risks of medical devices and imaging technologies.

RESULTS

To be useful in regulatory BRA, quantitative methods need to: aggregate multiple benefits and risks, incorporate qualitative considerations, account for uncertainty, and make clear whose preferences/priorities are being used. Each quantitative method performs differently across these criteria and little is known about how BRA estimates and conclusions vary by approach. While no specific quantitative method is likely to be the strongest in all of the important areas, quantitative methods may have a place in BRA of medical devices and radiology.

DISCUSSION

Quantitative BRA approaches have been more widely applied in medicines, with fewer BRAs in devices. Despite substantial differences in characteristics of pharmaceuticals and devices, BRA methods may be as applicable to medical devices and imaging technologies as they are to pharmaceuticals. Further research to guide the development and selection of quantitative BRA methods for medical devices and imaging technologies is needed.

摘要

原理与目标

做出监管性上市许可决定的卫生机构采用定性和定量方法来评估与医疗干预相关的预期益处和预期风险。然而,对于药品或医疗器械,包括成像技术,没有监管机构一直统一使用的通用标准方法来进行效益-风险评估(BRA)。经济学、卫生服务研究和健康结局研究采用定量方法来引出利益相关者的偏好、确定优先事项以及对健康状况和健康干预效果进行建模。

材料与方法

概述了医疗器械BRA面临的挑战,突出了放射学中的额外障碍。使用在平衡医疗器械和成像技术的益处和风险方面很重要的标准,对三种定量方法——多标准决策分析、健康结局建模和陈述性选择调查——进行了评估。

结果

为了在监管性BRA中有用,定量方法需要:汇总多种益处和风险、纳入定性考虑因素、考虑不确定性,并明确使用的是哪些人的偏好/优先事项。每种定量方法在这些标准上的表现各不相同,对于BRA估计和结论如何因方法而异知之甚少。虽然没有一种特定的定量方法可能在所有重要领域都是最强的,但定量方法在医疗器械和放射学的BRA中可能有一席之地。

讨论

定量BRA方法在药品中应用得更为广泛,在医疗器械中的BRA较少。尽管药品和医疗器械的特性存在很大差异,但BRA方法可能对医疗器械和成像技术与对药品一样适用。需要进一步开展研究,以指导医疗器械和成像技术定量BRA方法的开发和选择。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验